Literature DB >> 26254625

Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.

Junyi Wang1, Bin Zhang2, Wensheng Liu3, Yongxia Zhang4, Xuebing Di5, Yanmei Yang3, Dangui Yan3.   

Abstract

The rearranged during transfection (RET) gene is a proto-oncogene; active mutations frequently occur in medullary thyroid carcinoma (MTC). This study investigated the spectrum of germline RET mutations and clinical features in Chinese hereditary MTC patients. A total of 53 family members from 11 different hereditary MTC families were recruited for detection of RET exon 8, 10, 11, 13, 14, 15, and 16 mutations, in genomic DNA from peripheral blood leucocytes using polymerase chain reaction (PCR) and direct DNA sequencing. Of the 53 participants, eight different germline RET mutations were detected in 37 individuals. These RET mutations were distributed in exons 10, 11, 13, and 16. The most frequent RET mutation was localized at exon 11 codon 634 (67.6 %; 25/37) and the most prevalent mutation was C634R (37.8 %; 14/37). The most frequent phenotype was multiple endocrine neoplasia type 2A (MEN2A). The incidences of MTC, pheochromocytoma, and hyperparathyroidism in the MEN2A patients were 100, 36.4 and 18.2 %, respectively. The phenotype of families with Y606C or L790F mutation was categorized as familial medullary thyroid carcinoma. Moreover, one proband was identified with multiple endocrine neoplasia type 2B and carried a de novo mutation of M918T. Two families with C618S/Y mutation were categorized as unclassified multiple endocrine neoplasia type 2. Our results further substantiate that most germline mutations of the RET proto-oncogene were localized at codon 634 in Chinese hereditary MTC patients and carriers. RET mutation at codon 634 was always associated to the phenotype of MEN2A. Screening of RET mutations should be probably limited to exons 10, 11, 13 and 16 initially to be cost-effective in China.

Entities:  

Keywords:  Cancer; Germline mutation; Medullary thyroid carcinoma; RET proto-oncogene; Thyroid

Mesh:

Substances:

Year:  2016        PMID: 26254625     DOI: 10.1007/s10689-015-9828-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  25 in total

Review 1.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

2.  Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations.

Authors:  Guido Fitze; Mandy Schierz; Jan Bredow; Hans D Saeger; Dietmar Roesner; Hans K Schackert
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

Review 3.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

Review 4.  Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma.

Authors:  Z W Baloch; V A LiVolsi
Journal:  Thyroid       Date:  2001-07       Impact factor: 6.568

5.  A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.

Authors:  I Berndt; M Reuter; B Saller; K Frank-Raue; P Groth; M Grussendorf; F Raue; M M Ritter; W Höppner
Journal:  J Clin Endocrinol Metab       Date:  1998-03       Impact factor: 5.958

6.  Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma.

Authors:  H J Karga; M K Karayianni; D A Linos; S C Tseleni; K D Karaiskos; P D Papapetrou
Journal:  Eur J Endocrinol       Date:  1998-10       Impact factor: 6.664

7.  Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan.

Authors:  Chin-Feng Chang; Wei-Shiung Yang; Yi-Ning Su; I-Ling Wu; Tien-Chun Chang
Journal:  J Formos Med Assoc       Date:  2009-05       Impact factor: 3.282

8.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

9.  RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome.

Authors:  Marcia K Puñales; Hans Graf; Jorge L Gross; Ana Luiza Maia
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

10.  RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.

Authors:  Rossella Elisei; Cristina Romei; Barbara Cosci; Laura Agate; Valeria Bottici; Eleonora Molinaro; Mariangela Sculli; Paolo Miccoli; Fulvio Basolo; Lucia Grasso; Furio Pacini; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2007-09-25       Impact factor: 5.958

View more
  6 in total

1.  Genetic and Clinical Features of Medullary Thyroid Carcinoma: The Experience of a Single Center in Costa Rica.

Authors:  Javier Calvo; Gabriel Torrealba; Adriana Sáenz; Carlos Santamaría; Estela Morera; Silvia Alvarado; Yolanda Roa; Michelle González
Journal:  J Cancer Epidemiol       Date:  2016-11-27

2.  Distribution of RET Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994-2014: A Nationwide Study.

Authors:  Jes Sloth Mathiesen; Jens Peter Kroustrup; Peter Vestergaard; Kirstine Stochholm; Per Løgstrup Poulsen; Åse Krogh Rasmussen; Ulla Feldt-Rasmussen; Mette Gaustadnes; Torben Falck Ørntoft; Thomas van Overeem Hansen; Finn Cilius Nielsen; Kim Brixen; Christian Godballe; Anja Lisbeth Frederiksen
Journal:  Thyroid       Date:  2017-01-13       Impact factor: 6.568

3.  ASSOCIATION OF RS2435357 AND RS1800858 POLYMORPHISMS IN RET PROTO-ONCOGENE WITH HIRSCHSPRUNG DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS.

Authors:  Abdolhamid Amooee; Mohamad Hosein Lookzadeh; Seyed Reza Mirjalili; Seyed Mohsen Miresmaeili; Kazem Aghili; Masoud Zare-Shehneh; Hossein Neamatzadeh
Journal:  Arq Bras Cir Dig       Date:  2019-10-21

Review 4.  Multiple endocrine neoplasia 2: an overview.

Authors:  B Saravana-Bawan; J D Pasternak
Journal:  Ther Adv Chronic Dis       Date:  2022-02-25       Impact factor: 5.091

5.  Is new American Thyroid Association risk classification for hereditary medullary thyroid carcinoma applicable to Chinese patients? A single-center study.

Authors:  Xiwei Zhang; Dangui Yan; Junyi Wang; Hanfeng Wan; Yongxia Zhang; Yabing Zhang; Yuqin He; Wensheng Liu; Bin Zhang
Journal:  Chin J Cancer Res       Date:  2017-06       Impact factor: 5.087

6.  Multiple endocrine neoplasia 2 in Cyprus: evidence for a founder effect.

Authors:  P Fanis; N Skordis; S Frangos; G Christopoulos; E Spanou-Aristidou; E Andreou; P Manoli; M Mavrommatis; S Nicolaou; M Kleanthous; M A Cariolou; V Christophidou-Anastasiadou; G A Tanteles; L A Phylactou; V Neocleous
Journal:  J Endocrinol Invest       Date:  2018-02-02       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.